Interest of Metabolomic and Immune Profiling in the Development of Pancreatic Fistulas After Duodenopancreatectomy
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- occurrence of clinically significant FP and/or PAPP during hospitalization following pancreaticoduodenectomy.
研究概览
简要总结
Pancreatoduodenectomy is the standard surgical operation for benign or malign pancreatic lesions. Pancreatic Fistula (PF) or Postpancreatectomy Acute Pancreatitis (PPAP) are the major complications associated with that type of surgery. We need to develop preventive measures for these complications, which requires a better understanding of their physiopathology.
The aim of this prospective monocentric and observational study is to identify predictive biomarkers and/or risk factors for PF or PPAP using metabolomics. The Profiling of circulating metabolites is indeed an original and promising approach for this purpose. We will also investigate the patient's immune status and its association with the occurrence of post-surgical complications.
Participants will be adult patients scheduled to undergo elective pancreaticoduodenectomy. Surgery and patient's management will be as usual. During surgery, a fragment (0.1-0.2 g) of non-tumoral pancreatic tissue will be removed and frozen at -80°C for metabolomic analysis. For immunological assessment, 4 blood samples will be collected (before surgery and then 7 days, 1 and 3 months after, blood sampling).
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients scheduled to undergo elective pancreaticoduodenectomy
- •Non-opposition of the subject to participate in the study.
- •Affiliated to the French social security system (CMU included).
排除标准
- •Emergent surgery.
- •Pregnant patients.
- •Refusal to participate or inability to provide informed consent.
- •Patient under legal protection (individuals under guardianship by court order).
结局指标
主要结局
occurrence of clinically significant FP and/or PAPP during hospitalization following pancreaticoduodenectomy.
时间窗: 3 months
次要结局
未报告次要终点
